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S204 Poster Session Ihave failed prior mobilization with G-CSF 6 chemotherapy. The
minimum and optimal cell dose for transplant was collected in
91% and 64% of the patients, respectively. Future studies should ex-
plore the safety and efficacy of P +G in front-line mobilization of
amyloidosis pts.
Table 1. Remobilization OutcomesNo. of Patients 11
Median age (range) 61 (48-73)
Gender, male (%) 10 (90.9)
Median CD341Cells/kg x 106 Collected
(range)
6.61 (1.63-17.67)No. of patients collecting $2 x 106 CD341
cells/kg (%)10 (90.9)No. of patients collecting $5 x 106 CD341
cells/kg (%)7 (63.6)No. of patients proceeding to transplant (%) 10 (90.9)
Median days to platelet engraftment (range) 19 (7-25)
Median days to neutrophil engraftment (range) 14 (6-27)124
G-CSF+/- PLERIXAFOR IS SUPERIOR TO CYCLOPHOSPHAMIDE + G/GM-
CSF FOR AUTOLOGOUS HEMATOPOIETIC STEM CELLS (AHSC) MOBILIZA-
TION
Miller, A.N., Hogan, K.R., Alexander, E., Schaub, C., Fouts, T.,
Stuart, R.K., Costa, L.J. Medical University of South Carolina, Charles-
ton, SC
Background:The idealmethod tomobilize AHSC is unknown. The
use of chemotherapy (mostly cyclophosphamide) + growth factors,
when compared with the use of growth factors only, has the advan-
tage of higher HSC yield and fewer mobilization failures but is asso-
ciated with more complications. The use of the CXCR-4/SDF-1
binding inhibitor plerixafor, added to growth factor, may overcome
the limitations to the use of growth factor mobilization without che-
motherapy
Methods: We have developed a cost-saving decision making algo-
rithm that utilizes the CD34+ count in the peripheral blood on the
4th day of G-CSF administration (PB-CD34+) and the target
CD34+ count for the specific patient (T-CD34+) to decide between
starting collection on day 4 and continuing G-CSF administration
only (G approach) or adding Plerixafor the night before each apher-
esis session and starting apheresis on day 5 (G + P approach) (MUSC
algorithm, presented at 2010 tandemmeeting).We compared the ef-
ficacy of AHSCmobilization for patients with lymphoma ormultiple
myeloma utilizing theMUSC algorithm (MA cohort) with an histor-
ical series of patients undergoing mobilization with cyclophospha-
mide 2000 mg/m2 followed by G-CSF and/or GM-CSF (CY
cohort).
Results: Overall 28 individuals (9 on G and 19 on G + P) are in-
cluded in MA and 81 in CY. Patient’s characteristics are displayed
in table 1. The mobilization failure rate was 0% in MA vs. 22% in
CY (P5 0.01). Of the 18 patients who failed mobilization in CY,
10 completed collection in a subsequent mobilization attempt.
None of patients in MA and 4 patients in CY had infectious compli-
cations requiring hospitalization during mobilization. Patients com-
pleting collection in MA had in average 1.68 days of apheresis, vs.
1.73 in CY (P5 n.s.). The median yield of CD34+/kg was 6.4 
106 (range 3-15.8) in MA vs. 7.7  106 (range 2.8-72.6) in CY
(P5 0.07). For the 19 patients in MA and 60 in CY who received
a first autologous transplant, the median interval between beginning
of mobilization and transplant D0 was 13 days (range 11-63) and 42
days (range 12-157) respectively (P\0.01). There were no differ-
ences between MA and CY approaches in time for absolute neutro-
phil count. 500/mm2 (median 12 days for both MA and CY) or
platelet count. 20,000/mm2 without platelet transfusion (median
12 days for both MA and CY).Conclusion:TheMUSCmobilization algorithm is reliable and pro-
vides faster and safer mobilization than the use of cyclophosphamide
+ growth factor.
Table 1. Characteristics of the patients
MA- N5 28 CY- N5 81Diagnosis
Multiple Myeloma 23 (82%) 33 (41%)
Lymphoma 5 (18%) 48 (59%)
Age
#60 17 (61%) 49 (60%)
.60 11 (39%) 32 (40%)Gender
Male 10 (36%) 42 (52%)
Female 18 (64%) 39 (48%)
Prior radiation 10 (36%) 14 (17%)Prior lines of therapy- Lymphomas
#2 5 (100%) 40 (83%)
.2 0 (0%) 8 (17%)Prior lines of therapy- Myeloma
1 10 (43%) 13 (39%)
.1 13 (57%) 20 (61%)Prior lenalidomide 14 (61%) 7 (21%)125
PHASE I STUDY OF VORINOSTAT (SAHA) AFTER AUTOLOGOUS TRANS-
PLANT FOR PATIENTS WITH HIGH RISK LYMPHOMA
Hofmeister, C.C., Lozanski, G., Baiocchi, R.A., Hade, E.M.,
Benson, D.M., Blum, K., Porcu, P., Byrd, J.C., Devine, S.M. The Ohio
State University, Columbus, OH
Only the minority of patients with high risk or high intermediate
risk lymphoma will be cured with autologous transplant. SAHA has
shown activity in relapsed lymphoma and there is preclinical evi-
dence that HDACs may render lymphoma cells more susceptible
to host immune killing.
Methods:The primary objective was to assess safety and tolerabil-
ity of SAHA after BEAM-conditioned autologous transplant start-
ing day +60 for 21 consecutive days of a 28-day cycle for up to 11
cycles with 4 cohorts 100-400 mg of SAHA daily. Secondary ob-
jectives included preliminary clinical activity, NK and Treg recov-
ery, response to Prevnar vaccination at cycles 1/3/5, and quality of
life data (CES-D, BFI, and FACT-G). Patients were eligible with
DLBCL (induction failure, stage III/IV at relapse, age. 60, or el-
evated LDH at relapse), FL (transformed or 2+ prior regimens),
HL (primary refractory or PET positive after salvage), MCL, or
T-cell NHL.
Results: 10 lymphoma patients (median age 59 y.o, range 25-75)
have been treated thus far with FL (1), MCL (4), NS-HL (1),
PTCL (2), ALK-1 negative ALCL (1), and angioimmunoblastic
T-cell (1). Two pts had a PR after salvage chemotherapy pre-trans-
plant while the remaining 8 were in a CR. All patients were in a CR
post transplant and three patients (200 mg SAHA cohort) have suf-
fered progressive disease (1 after cycle 10, 1 after cycle 3, and 1 after
cycle 1). Drug-related adverse events consisted of two episodes of
grade 4 neutropenia (neither was dose-limiting), two patients suf-
fered grade 3 neutropenia, two with grade 3 rash/pruritus, and one
with grade 3 anorexia which was dose-limiting. The other DLT
was persistent grade 2 neutropenia thought to be clinically signifi-
cant. Preliminary analysis of peripheral blood flow cytometry
(n5 6) obtained at the beginning of odd numbered cycles showed
that patients with progressive disease had decreases over time in
the%of late activatedCD3 +HLA-DR+ andCD3 +CD86 +T-cells
with increased CD3 +CD16 + CD56dim NKT cells and
CD4 +CD25 + CD127- Tregs.
Conclusion:This ongoing phase I study of SAHA is accruing at the
300 mg SAHA dose level and has more neutropenia in the post auto-
graft population. Additional flow cytometry and quality of life data
